Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
COGT Stock Forecast 2026-2027
$31.02
Current Price
$5.30B
Market Cap
Buy 11
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to COGT Price Targets
+132.1%
To High Target of $72.00
+77.3%
To Median Target of $55.00
+12.8%
To Low Target of $35.00
COGT Price Momentum
-11.3%
1 Week Change
-13.5%
1 Month Change
+356.2%
1 Year Change
-12.7%
Year-to-Date Change
-29.1%
From 52W High of $43.73
+465.5%
From 52W Low of $5.49
📊 TOP ANALYST CALLS
Did COGT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Cogent Biosciences is one of their latest high-conviction picks.
Latest COGT Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, COGT has a bullish consensus with a median price target of $55.00 (ranging from $35.00 to $72.00). The overall analyst rating is Strong Buy (9.1/10). Currently trading at $31.02, the median forecast implies a 77.3% upside. This outlook is supported by 11 Buy, 2 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
COGT Analyst Ratings
11
Buy
2
Hold
0
Sell
COGT Price Target Range
Low
$35.00
Average
$55.00
High
$72.00
Current: $31.02
Latest COGT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for COGT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 29, 2026 | Wedbush | David Nierengarten | Outperform | Reiterates | $55.00 |
| May 6, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Mar 17, 2026 | Wedbush | Outperform | Reiterates | $N/A | |
| Mar 16, 2026 | Jefferies | Faisal Khurshid | Buy | Assumes | $55.00 |
| Feb 18, 2026 | Piper Sandler | Overweight | Maintains | $N/A | |
| Jan 21, 2026 | Wedbush | Outperform | Reiterates | $N/A | |
| Jan 6, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Dec 19, 2025 | JP Morgan | Overweight | Maintains | $N/A | |
| Dec 8, 2025 | Needham | Hold | Reiterates | $N/A | |
| Nov 13, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Nov 11, 2025 | Baird | Neutral | Maintains | $N/A | |
| Nov 10, 2025 | Leerink Partners | Outperform | Maintains | $N/A | |
| Nov 4, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Oct 21, 2025 | JP Morgan | Overweight | Maintains | $N/A | |
| Oct 16, 2025 | Stifel | Hold | Initiates | $N/A | |
| Sep 3, 2025 | Raymond James | Strong Buy | Initiates | $N/A | |
| Aug 25, 2025 | Guggenheim | Buy | Maintains | $N/A | |
| Aug 7, 2025 | JP Morgan | Overweight | Maintains | $N/A | |
| Aug 6, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Jul 18, 2025 | Citigroup | Buy | Maintains | $N/A |
Cogent Biosciences, Inc. (COGT) Competitors
The following stocks are similar to Cogent Biosciences based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
COGT
Cogent Biosciences
mkt cap
5.97B
Cogent Biosciences, Inc. (COGT) Financial Data
Valuation Metrics
Market Cap
$5.30B
Enterprise Value
$5.04B
P/E Ratio
N/A
PEG Ratio
-34.3x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+16.3%
Current Ratio
15.1x
Debt/Equity
39.3x
ROE
-85.7%
ROA
-38.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Cogent Biosciences, Inc. (COGT) Business Model
About Cogent Biosciences, Inc.
What They Do
Develops precision therapies for genetically defined diseases.
Business Model
Cogent Biosciences operates as a clinical-stage biopharmaceutical company, generating revenue through the development and commercialization of innovative small-molecule therapies. Its primary focus is on advancing its lead candidates through clinical trials, with the potential for future partnerships and collaborations that can enhance its research capabilities and market reach.
Additional Information
Founded in 2016 and based in Cambridge, Massachusetts, Cogent Biosciences emphasizes the modulation of the tumor microenvironment and immune-regulatory pathways in oncology. The company is targeting significant unmet medical needs in precision medicine, particularly with its CSF1R inhibitor and CGT9486 for various tumor indications, which could position it favorably in the competitive biopharmaceutical landscape.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
258
CEO
Mr. Andrew R. Robbins M.B.A.
Country
United States
IPO Year
2020
Website
www.cogentbio.comCogent Biosciences, Inc. (COGT) Latest News & Analysis
Latest News
Quick Summary
Bezuclastinib shows a significant improvement in median progression-free survival for GIST patients at 16.5 months, compared to 9.2 months with the active comparator (HR=0.50, p<0.001).
Why It Matters
Bezuclastinib's success in GIST patients indicates a breakthrough in treatment, potentially boosting the company's market position and attracting investor interest in its stock.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
The NDA for the drug has been accepted with Priority Review, following Breakthrough Therapy Designation. The PDUFA date is set for November 30, 2026.
Why It Matters
The NDA acceptance and Priority Review indicate potential expedited approval for a promising therapy, impacting future revenue projections and stock performance by November 2026.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Cogent Biosciences Announces Participation in the 2026 Jefferies Global Healthcare Conference
10 days ago
Quick Summary
Waltham, Massachusetts, and Boulder, Colorado, are mentioned; however, no specific financial information or context is provided in the excerpt.
Why It Matters
The mention of Waltham and Boulder may indicate significant business developments or partnerships in tech or biotech sectors, potentially impacting stock performance and market trends.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Cogent Biosciences will present results from its APEX trial and JAK2 V617F program at the EHA Congress in Stockholm, June 11-14, 2026.
Why It Matters
Results from the APEX trial and the JAK2 V617F program could indicate potential breakthroughs in treatment, impacting Cogent Biosciences' stock performance and market position.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results
1 month ago
Quick Summary
Bezuclastinib is set for dual launches in Systemic Mastocytosis and GIST, with Phase 3 PEAK trial data to be presented at the 2026 ASCO meeting. The company reported $866.4M in cash, funding operations until 2028.
Why It Matters
Bezuclastinib's dual launches and upcoming pivotal data presentation signal potential growth and revenue for the company, while strong cash reserves ensure operational stability through 2028.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Waltham, Massachusetts, and Boulder, Colorado, have been mentioned, but no specific financial news or developments are provided in the excerpt.
Why It Matters
The mention of Waltham and Boulder could indicate regional economic developments or company expansions, impacting local markets and investment opportunities.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About COGT Stock
What is Cogent Biosciences, Inc.'s (COGT) stock forecast for 2026?
Based on our analysis of 4 Wall Street analysts, Cogent Biosciences, Inc. (COGT) has a median price target of $55.00. The highest price target is $72.00 and the lowest is $35.00.
Is COGT stock a good investment in 2026?
According to current analyst ratings, COGT has 11 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $31.02. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for COGT stock?
Wall Street analysts predict COGT stock could reach $55.00 in the next 12 months. This represents a 77.3% increase from the current price of $31.02. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Cogent Biosciences, Inc.'s business model?
Cogent Biosciences operates as a clinical-stage biopharmaceutical company, generating revenue through the development and commercialization of innovative small-molecule therapies. Its primary focus is on advancing its lead candidates through clinical trials, with the potential for future partnerships and collaborations that can enhance its research capabilities and market reach.
What is the highest forecasted price for COGT Cogent Biosciences, Inc.?
The highest price target for COGT is $72.00 from at , which represents a 132.1% increase from the current price of $31.02.
What is the lowest forecasted price for COGT Cogent Biosciences, Inc.?
The lowest price target for COGT is $35.00 from at , which represents a 12.8% increase from the current price of $31.02.
What is the overall COGT consensus from analysts for Cogent Biosciences, Inc.?
The overall analyst consensus for COGT is bullish. Out of 4 Wall Street analysts, 11 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $55.00.
How accurate are COGT stock price projections?
Stock price projections, including those for Cogent Biosciences, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 6, 2026 3:08 AM UTC